Layer 04 · Intelligence
BD / Pharma / watcher
Streaming · 14:32:08 ET
Bloomberg-style intelligence on drugs and trials coming to market — engineered for site BD teams to land sponsors first.
Filters
Live Opportunities · ClinicalTrials.gov v2 cached· 0 saved
NCT07610473
Phase 2
A Phase 2 Double-blind, Randomised, Placebo-controlled Trial to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of DT-101 in Adults With Major Depressive Disorder Receiving Pharmacological Therapy for Depression
Draig Therapeutics Ltd
Major Depressive Disorde
Status
Recruiting
Sites
2
Start
2026-05
P. Compl.
2027-05
Match · —70/100
Moderate Gap Fit
TA · phase default
P(award) 55%
| Visit-Based Revenue | $300,000 |
| Startup Fee | $25,000 |
| Enrollment Milestone Fees | $15,000 |
| Closeout Fee | $10,000 |
| Screen-Fail Revenue | $3,200 |
| Other Fixed / Milestone | $5,000 |
| Gross Revenue Potential | $358,200 |
| Probability-Weighted | $197,010 |
Source · Other · Phase II default
NCT06529029
Phase 2
Efficacy of Low Amplitude Pulse Seizure Therapy Versus Standard Ultra-Brief Right Unilateral Electroconvulsive Therapy in Remission of Suicidal Ideation
Michigan State University
Suicidal IdeationMajor Depressive DisordeSchizo Affective Disorde
Status
Recruiting
Sites
1
Start
2024-07-03
P. Compl.
2026-07-01
Match · Psychiatry90/100
Strong Gap Fit
TA · phase default
P(award) 55%
| Visit-Based Revenue | $300,000 |
| Startup Fee | $25,000 |
| Enrollment Milestone Fees | $15,000 |
| Closeout Fee | $10,000 |
| Screen-Fail Revenue | $3,200 |
| Other Fixed / Milestone | $5,000 |
| Gross Revenue Potential | $358,200 |
| Probability-Weighted | $197,010 |
Source · Other · Phase II default
NCT06231563
Phase 2
Examining Ketamine Effects on Depression, Neuroplasticity, and Inflammation in Veterans With Parkinson's Disease
VA Office of Research and Development
Parkinson's Disease
Status
Recruiting
Sites
1
Start
2026-03-01
P. Compl.
2029-09-30
Match · Neurology70/100
Moderate Gap Fit
TA · phase default
P(award) 55%
| Visit-Based Revenue | $345,000 |
| Startup Fee | $28,750 |
| Enrollment Milestone Fees | $17,250 |
| Closeout Fee | $11,500 |
| Screen-Fail Revenue | $3,680 |
| Other Fixed / Milestone | $5,750 |
| Gross Revenue Potential | $411,930 |
| Probability-Weighted | $226,562 |
Source · Neurology · Phase II default
NCT06053567
Phase 3
Efficacy and Implementation of Exercise-based Smoking Cessation Treatment for Adults With High Anxiety Sensitivity.
Jasper A. Smits
Nicotine Dependence
Status
Recruiting
Sites
1
Start
2023-12-27
P. Compl.
2029-03-31
Match · —90/100
Strong Gap Fit
TA · phase default
P(award) 70%
| Visit-Based Revenue | $546,000 |
| Startup Fee | $38,750 |
| Enrollment Milestone Fees | $23,250 |
| Closeout Fee | $15,500 |
| Screen-Fail Revenue | $4,800 |
| Other Fixed / Milestone | $7,750 |
| Gross Revenue Potential | $636,050 |
| Probability-Weighted | $445,235 |
Source · Other · Phase III default
FDA enrichment
GUHIO Nicotine Patch · Guangxi Keyun E-commerce Co., Ltd.
Nicotine Patch · Guangzhou Yunzhen Trading Co., Ltd.
NCT06402955
Phase 2
Identifying the Neural Basis of Depression in Parkinson's Disease
Yale University
Parkinson's DiseaseMajor Depressive Disorde
Status
Recruiting
Sites
1
Start
2024-09-01
P. Compl.
2029-01-01
Match · Neurology70/100
Moderate Gap Fit
TA · phase default
P(award) 55%
| Visit-Based Revenue | $345,000 |
| Startup Fee | $28,750 |
| Enrollment Milestone Fees | $17,250 |
| Closeout Fee | $11,500 |
| Screen-Fail Revenue | $3,680 |
| Other Fixed / Milestone | $5,750 |
| Gross Revenue Potential | $411,930 |
| Probability-Weighted | $226,562 |
Source · Neurology · Phase II default
NCT06564818
Phase 3
A Phase III, Placebo-Controlled, Randomized, Double-Blind Trial of Oral Doses of CYB003 to Assess Combined Safety and Efficacy in Humans With Major Depressive Disorder
Cybin IRL Limited
Major Depressive Disorde
Status
Recruiting
Sites
46
Start
2024-12-17
P. Compl.
2026-08
Match · —99/100
Strong Gap Fit
TA · phase default
P(award) 70%
| Visit-Based Revenue | $546,000 |
| Startup Fee | $38,750 |
| Enrollment Milestone Fees | $23,250 |
| Closeout Fee | $15,500 |
| Screen-Fail Revenue | $4,800 |
| Other Fixed / Milestone | $7,750 |
| Gross Revenue Potential | $636,050 |
| Probability-Weighted | $445,235 |
Source · Other · Phase III default
NCT07065240
Phase 2
A Randomized, Parallel-Group, Double-Blind, Placebo-Controlled, Monotherapy Study of the Efficacy, Safety, and Tolerability of SPT-300 in Adults With Major Depressive Disorder (MDD), With or Without Anxious Distress
Seaport Therapeutics
Major Depressive DisordeMajor Depressive Disorde
Status
Recruiting
Sites
59
Start
2025-06-19
P. Compl.
2027-03
Match · —80/100
Strong Gap Fit
TA · phase default
P(award) 55%
| Visit-Based Revenue | $300,000 |
| Startup Fee | $25,000 |
| Enrollment Milestone Fees | $15,000 |
| Closeout Fee | $10,000 |
| Screen-Fail Revenue | $3,200 |
| Other Fixed / Milestone | $5,000 |
| Gross Revenue Potential | $358,200 |
| Probability-Weighted | $197,010 |
Source · Other · Phase II default
Study Contracting Gap · placeholder · TA × month projected revenue
pipeline coverage 27%→target 38%
| TA | Oct | Nov | Dec | Jan | Feb | Mar | Total Gap |
|---|---|---|---|---|---|---|---|
| Oncology | $240K | $280K | $310K | $290K | $320K | $360K | $1800K |
| Cardiology | $120K | $140K | $170K | $150K | $160K | $190K | $930K |
| Neurology | $90K | $110K | $130K | $140K | $150K | $170K | $790K |
| Endocrinology | $180K | $200K | $220K | $210K | $230K | $260K | $1300K |
| Immunology | $60K | $80K | $90K | $110K | $120K | $140K | $600K |
| Dermatology | $40K | $50K | $60K | $55K | $65K | $75K | $345K |
Total projected gap · $5765K across 6 monthsHigher-fit opportunities above will reduce these cells.
1,284
Active trials tracked
38
Phase II → III moves · 30d
$842B
Sponsor R&D · ttm
12
Hot leads for site
Phase II → III Pipeline Signals
live feed| Asset | Sponsor | TA | Move | Sites Δ | Detected |
|---|---|---|---|---|---|
| TLF-3284 | Lilly | Endocrinology | IIIII | +22 sites | 2025-10-09 |
| MK-0411 | Merck | Oncology | IIIII | +38 sites | 2025-10-07 |
| AZ-9912 | AstraZeneca | Cardiology | IbII | +12 sites | 2025-10-04 |
| PF-2255 | Pfizer | Immunology | IIIII | +44 sites | 2025-10-02 |
| BMS-714 | BMS | Oncology | IIIII | +19 sites | 2025-09-29 |
Contracting Gap · by TA
Contracted Gap (opportunity)
Trial Opportunity Cards· 8 matches
NCT06241884Phase III
Metastatic NSCLC
Pfizer · Oncology
Fit score92/100
142 sitesRecruiting
NCT06198302Phase III
Obesity / GLP-1
Eli Lilly · Endocrinology
Fit score87/100
88 sitesRecruiting
NCT06112447Phase II
Sickle Cell
Novartis · Hematology
Fit score64/100
41 sitesNot Yet
NCT06309901Phase III
HFpEF
AstraZeneca · Cardiology
Fit score81/100
96 sitesRecruiting
NCT06277712Phase II
TNBC
Merck · Oncology
Fit score79/100
52 sitesRecruiting
NCT06184221Phase III
Cystic Fibrosis
Vertex · Pulmonology
Fit score71/100
34 sitesActive
NCT06091334Phase II
Crohn's
BMS · Gastroenterology
Fit score58/100
28 sitesNot Yet
NCT06304556Phase III
Wet AMD
Regeneron · Ophthalmology
Fit score76/100
62 sitesRecruiting
Therapeutic-Area Heatmap · trials by phase
| TA | Ph I | Ph II | Ph III | Ph IV | Total |
|---|---|---|---|---|---|
| Oncology | 28 | 64 | 142 | 18 | 252 |
| Cardiology | 14 | 31 | 96 | 9 | 150 |
| Endocrinology | 12 | 34 | 88 | 14 | 148 |
| Neurology | 18 | 27 | 64 | 7 | 116 |
| Immunology | 16 | 28 | 71 | 8 | 123 |
| Hematology | 8 | 19 | 41 | 4 | 72 |
| Pulmonology | 6 | 12 | 34 | 3 | 55 |
| Gastroenterology | 7 | 16 | 28 | 3 | 54 |
Cell intensity = trial count · darker sage = denser opportunity for that TA × phase
Pipeline Coverage Forecast · 5 quarters
- Contracted
- Expected (target)
- TA-relevant
Current coverage
27%
Target by Q1 27
38%
Gap to close
11pt
Sponsor & CRO Intelligence
updated 4m ago| Org | Active Trials | YoY Growth | Top TA | Contact Persona | |
|---|---|---|---|---|---|
| Pfizer | 412 | +8% | Oncology | Site Network Lead | |
| Eli Lilly | 287 | +14% | Endocrinology | Clinical Ops Dir. | |
| Merck | 391 | +6% | Oncology | Feasibility Mgr. | |
| AstraZeneca | 264 | +9% | Cardiology | Site Activation | |
| Novartis | 318 | +4% | Hematology | Country Head | |
| IQVIA (CRO) | 1,240 | +11% | Multi | Sr. Site Manager | |
| Parexel (CRO) | 612 | +7% | Neurology | Strategic Sites |